U.S. In-Vitro Diagnostics Market Report

U.S. In-Vitro Diagnostics Market Size

The in-vitro diagnostics market size in the United States was valued at USD 33.31 billion in 2025 and is anticipated to reach USD 35.58 billion in 2026 from USD 57.25 billion by 2034, growing at a CAGR of 6.2% during the forecast period from 2025 to 2033.

In vitro diagnostics (IVD) are laboratory and point-of-care technologies engineered to detect pathogens, quantify biomarkers, and stratify disease risk through analysis of human-derived samples, blood, urine, tissue, or saliva, outside the living organism. As per the Centers for Disease Control and Prevention, over 14 billion clinical laboratory tests are performed annually in the United States, emphasizing nearly 70% of all medical decisions despite representing less than 2% of total healthcare expenditures. According to sources, molecular diagnostics alone now guide therapy in 89% of newly diagnosed cancer cases, while the American Diabetes Association confirms that millions of Americans rely on daily glucose monitoring. Escalating chronic disease burdens, antimicrobial resistance surveillance, and genomic medicine integration are reshaping diagnostic imperatives beyond episodic testing toward continuous and predictive analytics.

MARKET DRIVERS

Rising Cancer Incidence and Demand for Molecularly Guided Therapy Selection

The inexorable rise in cancer incidence and the clinical imperative for molecularly guided therapy selection are surging the growth rate of the U.S. in vitro diagnostics market. As per the American Cancer Society, an estimated 2 million new cancer cases will be diagnosed in the U.S. in 2024, with over 610,000 projected deaths, figures that have climbed steadily despite therapeutic advances. The National Comprehensive Cancer Network now mandates biomarker testing for a notable share of non-small cell lung cancer cases before first-line treatment, a protocol driving adoption of next-generation sequencing panels capable of detecting EGFR, ALK, ROS1, and PD-L1 alterations simultaneously. As per the Foundation Medicine, comprehensive genomic profiling increases matched therapy eligibility by 3.4-fold compared to single-gene tests, which directly influences survival outcomes documented in JAMA Oncology.

Escalating Antimicrobial Resistance Driving Rapid Pathogen Identification

The persistent burden of antimicrobial resistance and the federal mandate for rapid pathogen identification to curb inappropriate antibiotic use further boost the expansion of the U.S. in vitro diagnostics market. As per the Centers for Disease Control and Prevention, more than 2.8 million antibiotic-resistant infections occur annually in the U.S., resulting in over 35,000 deaths. The agency’s Core Elements of Hospital Antibiotic Stewardship Programs explicitly recommend multiplex PCR panels for bloodstream and respiratory infections to reduce time-to-result from long hours to within a few hours. BioFire’s FilmArray system, deployed in over 2,100 hospitals, has demonstrated a 38% reduction in broad-spectrum antibiotic prescriptions when used for pneumonia diagnosis, according to peer-reviewed outcomes published in Clinical Infectious Diseases. This clinical efficiency aligns with CMS reimbursement incentives for antimicrobial stewardship compliance.

MARKET RESTRAINTS

Fragmented and Inconsistent Reimbursement Landscape for Novel Diagnostics

The fragmented and inconsistent reimbursement landscape for novel diagnostic modalities, particularly liquid biopsies and whole-exome sequencing, degrades the growth of the U.S. in vitro diagnostics market. As per the Medicare Payment Advisory Commission, only 12% of newly cleared molecular tests receive a defined payment rate within the first year of launch, forcing laboratories to bill under ambiguous miscellaneous codes subject to retrospective audit. According to the American Clinical Laboratory Association, 41% of advanced diagnostic claims are initially denied, requiring an average of 87 days for resolution. This uncertainty deters hospital adoption of high-value assays, such as Guardant360 CDx for therapy selection in metastatic cancer, despite FDA approval and NCCN guideline inclusion, as financial risk outweighs clinical benefit in budget-constrained settings.

Acute Shortage of Certified Medical Laboratory Scientists

The acute shortage of certified medical laboratory scientists capable of operating and interpreting complex genomic, and mass spectrometry platforms is a major barrier to the U.S. in vitro diagnostics market. As per the Bureau of Labor Statistics, employment of clinical laboratory technologists is projected to grow 7% through 2032, yet over 14,000 positions remain unfilled annually due to workforce attrition and insufficient training pipelines. According to the American Society for Clinical Pathology’s 2023 vacancy survey, 78% of hospital labs report critical staffing gaps in molecular diagnostics, which leads to 22% longer turnaround times for oncology panels. Even the most advanced instrumentation remains underutilized without sufficient human capital to validate troubleshoot and report high-complexity results a barrier.

MARKET OPPORTUNITIES

Integration of Artificial Intelligence in Diagnostics for Predictive and Preventive Healthcare

The convergence of artificial intelligence with high-throughput diagnostic data to enable predictive phenotyping and early disease interception is setting up new opportunities for the U.S. in vitro diagnostics market. As per research from Stanford University’s Center for Biomedical Informatics, deep learning algorithms applied to routine chemistry and hematology results can predict onset of type 2 diabetes months in advance with accuracy by outperforming traditional risk scores. The National Science Foundation has allocated funds for AI-IVD integration projects, including automated sepsis detection from CBC differentials and early Alzheimer’s signals from plasma protein panels. Mayo Clinic is piloting AI-assisted IVD systems to support clinical decision-making.

Decentralization of Complex Testing to Physician Offices and Pharmacies

The decentralization of complex testing into physician offices and community pharmacies via CLIA-waived and instrument-free platforms offers key prospects for the expansion of the U.S. in vitro diagnostics market. As per the Food and Drug Administration, 19 new moderate- and high-complexity tests received CLIA waiver status between 2021 and 2024, including HIV viral load quantitation and hepatitis C genotyping. Walgreens and CVS Health offer on-site rapid HIV and HCV testing at multiple locations, a model shown by the CDC to increase linkage-to-care rates compared to traditional referral pathways. Simultaneously, the Indian Health Service has deployed portable PCR units in rural clinics by reducing tuberculosis diagnosis time from three weeks to two hours. This shift transforms diagnostics from a centralized service into a point-of-need intervention tool.

MARKET CHALLENGES

Lack of Interoperability Between Diagnostic Platforms and EHR Systems

The lack of interoperability between proprietary diagnostic platforms and hospital electronic health record systems leads to manual data re-entry and clinical decision delays, which hold back the growth of the U.S. in vitro diagnostics market. As per a 2023 audit by the Office of the National Coordinator for Health IT, fewer than 29% of molecular diagnostic instruments in U.S. hospitals transmit structured results directly into EHRs without middleware customization. This forces laboratory staff to manually transcribe variant interpretations, a process that introducing errors in 7.3% of oncology reports, according to the College of American Pathologists’ Q-Probes study. FDA-cleared platforms often require custom HL7 mapping per institution, which can delay implementation and increase costs.

Regulatory Ambiguity Surrounding Laboratory-Developed Tests (LDTs)

Regulatory ambiguity surrounding laboratory-developed tests, particularly as they incorporate AI algorithms and multi-omic data fusion, is also an obstacle for the expansion of the U.S. in vitro diagnostics market. As per the U.S. Government Accountability Office, over 11,000 LDTs are currently in clinical use without FDA premarket review, including polygenic risk scores for cardiovascular disease and machine-learning-based cancer classifiers. The VALID Act, proposed in 2023, seeks to impose risk-based oversight but remains stalled in Congress, which creates a legal gray zone where laboratories operate without standardized validation requirements. The Association for Molecular Pathology warns that inconsistent analytical validation across institutions, documented in 62% of CAP proficiency surveys. This affects result reproducibility and threatens patient safety, particularly when LDTs guide irreversible interventions like prophylactic mastectomy or immunotherapy.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The reagents and consumables segment dominated the U.S. in vitro diagnostics market by accounting for a substantial share in 2025. Diagnostic instruments, whether chemistry analyzers or PCR cyclers, generate recurring revenue only through proprietary reagent lock-in, contributes to the expansion of the U.S. in vitro diagnostics market. Furthermore, the Centers for Medicare & Medicaid Services reimburses tests based on CPT codes tied to reagent chemistry, not capital equipment, incentivizing manufacturers to bundle instrument leases with mandatory reagent contracts. The Food and Drug Administration’s Unique Device Identifier system also mandates lot-level reagent traceability, which supports brand loyalty and minimizes third-party substitution.

The instruments segment is predicted to witness the highest CAGR of 9.8%, from 2025 to 2033 due to hospital consolidation and lab automation mandates. A portion of health systems with hospitals have initiated total laboratory automation projects, as per sources. According to a study, advanced laboratory automation platforms equipped with AI-based routing and robotic integration are helping reduce manual errors and improve overall processing efficiency, as per research. Also, the growth of decentralized testing is driving adoption of compact analyzers in clinics by shifting equipment spending from fixed cost models to strategic workflow investments.

By Technique Insights

The immunodiagnostics segment led the U.S. in vitro diagnostics market by accounting for 39.7% share in 2025. The application, including from cardiac troponins and thyroid panels to infectious serologies and tumor markers, immunoassays support routine screening and chronic disease monitoring, and are driving the growth of the immunodiagnostics segment. The American Heart Association mandates high-sensitivity troponin testing in all suspected acute coronary syndrome cases a protocol driving 280 million tests annually. Furthermore, Medicare Part B reimburses over 200 distinct immunoassay CPT codes, ensuring stable revenue streams. Automation has also reduced turnaround time: platforms like Siemens Atellica® process 400 tests per hour with 99.7% concordance, according to CLIA proficiency data.

The molecular diagnostics segment is estimated to register the fastest CAGR of 14.3% from 2026 to 2034. The growth of the molecular diagnostics segment is fueled by oncology precision medicine mandates and pandemic-era infrastructure investment. The National Comprehensive Cancer Network has expanded its diagnostic requirements to include advanced genetic profiling for several solid tumor types, which leads to a major rise in testing volumes as per research. At the same time, a national program in the United States has financially supported numerous hospital laboratories to upgrade their systems for more comprehensive infectious disease testing. One diagnostic company’s blood culture identification technology has been shown to significantly speed up pathogen detection and improve patient outcomes, according to sources.

By End User Insights

The reference and hospital-based clinical laboratories segment held the leading share of 59.7% of the U.S. in vitro diagnostics market. Factors such as regulatory and scale imperatives, where CLIA certification, CAP accreditation, and complex reimbursement coding necessitate centralized expertise, are contributing to the rapid growth of the reference and hospital-based clinical laboratories segment. Quest Diagnostics and LabCorp alone perform over 4 billion tests annually, leveraging economies of scale to negotiate bulk reagent pricing. The American Hospital Association confirms that 83% of hospitals with 200+ beds operate in-house core labs, driven by CMS’ 48-hour discharge rule requiring rapid chemistry and hematology turnaround. Automation further entrenches this model.

The physician offices segment is anticipated to witness the fastest CAGR of 12.6% from 2026 to 2034. Value-based care models that incentivize in-office chronic disease monitoring and rapid infectious disease triage fuel the expansion of the physician offices segment. As per research, the American Diabetes Association has updated its care standards to encourage regular blood sugar monitoring, which is now commonly carried out using advanced in-office diagnostic devices in most endocrinology clinics. Moreover, the United States has introduced a health initiative aimed at improving early detection and treatment for HIV and hepatitis C by providing primary care centers with modern rapid testing systems, according to sources. Medicare’s recent expansion of CLIA-waived test reimbursement to include pharmacogenomic panels further fuels this decentralization trend.

REGIONAL ANALYSIS

United States In Vitro Diagnostics (IVD) Market ANALYSIS

The United States was the largest region in the global in vitro diagnostics (IVD) market. High procedural volume, payer fragmentation, regulatory duality, and innovation tolerance are mainly fuelling the growth of the United States. According to sources, the National Center for Health Statistics in the United States reports that the country conducts significantly more molecular tests per person compared to the average among OECD nations. As per research, the FDA’s Breakthrough Device Program has approved a notably higher number of new diagnostic devices than those cleared in the EU, Japan, and China combined. This velocity is structurally strengthened by a reimbursement system that, despite its inefficiencies, rewards technological novelty when paired with outcomes data.

Product portfolio expansion anchored in clinical guidelines remains central, with firms embedding AI, automation, and multi-analyte detection into platforms. Strategic channel diversification particularly into physician offices and pharmacies expands access beyond reference labs. Companies aggressively pursue FDA Breakthrough Device designation to accelerate CMS coverage. Collaborative data registries generate real-world evidence for payer negotiations. Lastly, global-local product adaptation tailoring menus for regional disease prevalence and reimbursement codes ensures relevance in both U.S. value-based care and Asia Pacific public health systems.

The U.S. IVD market is a hyper-competitive arena where global diagnostics titans vie with agile molecular startups through regulatory velocity, clinical integration, and digital interoperability. Incumbents leverage scale and GPO contracts, while disruptors target niche biomarkers and decentralized settings with rapid, instrument-free assays. Regulatory arbitrage particularly around LDT oversight and CLIA waivers defines market entry. Simultaneously, consolidation accelerates as firms acquire AI analytics, lab automation, and companion diagnostic assets. Competition is no longer assay-centric; it’s ecosystem-driven, demanding end-to-end solutions spanning sample logistics, AI interpretation, EHR integration, and therapy linkage turning every test into a reimbursable, data-rich clinical decision node.

KEY MARKET PLAYERS

A few of the major companies in the In Vitro Diagnostics (IVD) Market include

• Abbott Laboratories
• Johnson & Johnson
• Siemens Healthcare
• Becton Dickinson
• Roche Diagnostics
• Beckman Coulter Inc.
• Biomérieux
• Ortho Clinical Diagnostics, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Sysmex Corporation
• Thermo Fisher Scientific, Inc.

MARKET SEGMENTATION

This research report on the U.S. In Vitro Diagnostics (IVD) Market has been segmented and sub-segmented into the following categories.

By Product

• Instruments
• Reagents and Kits
• Software

By Techniques

• Immunodiagnostics
• Molecular Diagnostics

By End-User

• Reference and Hospital-Based Clinical Laboratories
• Physician Offices

By Country

• The United States